Kaiser Health News reported that Amarin Corp.’s announcement in September of early findings for Vascepa (icosapent ethyl) highlights a trend that is worrying physicians, cardiovascular experts, and “pharma watchers” that companies will “promote new products, but withhold the detailed findings until much later.” Dr. Eric Strong, a hospitalist and clinical assistant professor at Stanford School of Medicine, argued, “Until all the data is available for review by the public and medical community, it’s really premature to see some of the cheerleading that’s being done.”

From the news release of the American Association for Justice.